These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Molecular characterization of diffuse malignant peritoneal mesothelioma. Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035 [TBL] [Abstract][Full Text] [Related]
3. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512 [TBL] [Abstract][Full Text] [Related]
4. Genomic landscape of pleural and peritoneal mesothelioma tumours. Hiltbrunner S; Fleischmann Z; Sokol ES; Zoche M; Felley-Bosco E; Curioni-Fontecedro A Br J Cancer; 2022 Nov; 127(11):1997-2005. PubMed ID: 36138075 [TBL] [Abstract][Full Text] [Related]
5. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. Dagogo-Jack I; Madison RW; Lennerz JK; Chen KT; Hopkins JF; Schrock AB; Ritterhouse LL; Lester A; Wharton KA; Mino-Kenudson M; Danziger N; Hung YP; Mata DA; Ross JS JCO Precis Oncol; 2022 Jun; 6():e2100422. PubMed ID: 35704798 [TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618 [TBL] [Abstract][Full Text] [Related]
7. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology. Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416 [TBL] [Abstract][Full Text] [Related]
8. Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features. Yang SR; Jayakumaran G; Benhamida J; Febres-Aldana CA; Fanaroff R; Chang J; Gedvilaite E; Villafania LB; Sauter JL; Offin M; Zauderer MG; Ladanyi M Clin Cancer Res; 2024 Jul; 30(13):2780-2789. PubMed ID: 38630790 [TBL] [Abstract][Full Text] [Related]
9. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769 [TBL] [Abstract][Full Text] [Related]
10. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study. Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Kasai T; Kushitani K; Takeshima Y; Hiroshima K; Iwasaki A; Nabeshima K Lung Cancer; 2023 Jan; 175():27-35. PubMed ID: 36442384 [TBL] [Abstract][Full Text] [Related]
11. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843 [TBL] [Abstract][Full Text] [Related]
12. Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant. Shinozaki-Ushiku A; Kohsaka S; Kage H; Oda K; Miyagawa K; Nakajima J; Aburatani H; Mano H; Ushiku T Pathol Int; 2020 Oct; 70(10):775-780. PubMed ID: 32583627 [TBL] [Abstract][Full Text] [Related]
13. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens. Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897 [TBL] [Abstract][Full Text] [Related]
14. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456 [TBL] [Abstract][Full Text] [Related]
15. Inactivation of Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962 [TBL] [Abstract][Full Text] [Related]
16. Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features. Michal M; Kravtsov O; Ross JS; Skanderová D; Martínek P; Mosaieby E; Mata DA; Williams EA; Hung YP Genes Chromosomes Cancer; 2023 May; 62(5):267-274. PubMed ID: 36515470 [TBL] [Abstract][Full Text] [Related]
17. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Borczuk AC; Pei J; Taub RN; Levy B; Nahum O; Chen J; Chen K; Testa JR Cancer Biol Ther; 2016; 17(3):328-35. PubMed ID: 26853494 [TBL] [Abstract][Full Text] [Related]